Lineage Cell Therapeutics
LCTX
LCTX
115 hedge funds and large institutions have $192M invested in Lineage Cell Therapeutics in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 27 increasing their positions, 35 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more ownership
Funds ownership: →
more funds holding
Funds holding: →
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
8% less capital invested
Capital invested by funds: $208M → $192M (-$16.6M)
23% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 35
Holders
115
Holding in Top 10
3
Calls
$1.49M
Puts
$617K
Top Buyers
| 1 | +$9.05M | |
| 2 | +$1.75M | |
| 3 | +$665K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$512K |
| 5 |
Rafferty Asset Management
New York
|
+$488K |
Top Sellers
| 1 | -$1.85M | |
| 2 | -$1.79M | |
| 3 | -$1.11M | |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$927K |
| 5 |
DC
Defender Capital
Charlotte,
North Carolina
|
-$631K |